BIFEPRUNOX DOSES FOR TREATING SCHIZOPHRENIA

The present disclosure is directed to a daily dose of bifeprunox for the treatment of a patient with schizophrenia. Such dose is effectively used in methods for treating schizophrenia comprising administering to a patient a p harmaceutical composition comprising an effective amount of at least one b...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	CASEY, DANIEL E, NEWCOMER, JOHN, PAUL, JEFF, WINSEMIUS, ANTJE A, YEUNG, PAUL P, HEISTERBERG, JENS, KROG JOSIASSEN, METTE, BARBATO, LUIGI M, PARDUE, ROSELINE, RAJE, SANGEETA, MALLING, DORTE, BOURIN, MICHEL, SHAPIRA, NATHAN A, DE VRIES, MICHIEL H, RAPAPORT, MARK, BUCH OSTERGARD, JETTE, POTKIN, STEVEN G, CHRISTENSEN, ELLEN B, DEBELLE, MARC, AHMED, SAEED
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present disclosure is directed to a daily dose of bifeprunox for the treatment of a patient with schizophrenia. Such dose is effectively used in methods for treating schizophrenia comprising administering to a patient a p harmaceutical composition comprising an effective amount of at least one bif eprunox compound, amongst other effects, resulting in a reduction of side ef fects associated with schizophrenia treatment such as: no weight gain, impro vement of non-fasting triglyceride levels and/or total cholesterol levels. T reatment effects are e.g. a reduction of PANSS total score in a patient and an increase of the time to deterioration of schizophrenia and improvement of psychotic symptoms.